Schlenk, R. F.; Weber, D.; Krzykalla, J. et al.
Randomized phase-III study of low-dose cytarabine and etoposide? plus ?/- all-<i>trans</i> retinoic acid in older unfit patients with <i>NPM1</i>-mutated acute myeloid leukemiaSCIENTIFIC REPORTS. Bd. 13. H. 1. 2023
Nowakowski, Grzegorz S.; Yoon, Dok Hyun; Mondello, Patrizia et al.
RE-MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola-BR), CAR-T therapies, and lenalidomide/rituximab (R2) based on real-world data in patients with relapsed/refractory diffuse large B-cell lymphomaANNALS OF HEMATOLOGY. Bd. 102. H. 7. 2023 S. 1773-1787
Hess, Georg; Vucinic, Vladan; Rejeski, Kai et al.
Real World Results of Brexucabtagene Autoleucel for Patients with Relapsed/Refractory Mantle Cell Lymphoma - First German/Swiss AnalysisBLOOD. Bd. 142. 2023
Zueger, Andrea; Fischbeck, Sabine; Weber, Martin et al.
Revision of the Advanced Cancer Patients' Distress Scale (ACPDS): a mixed-methods study among palliative patients and healthcare professionals in GermanyBMJ OPEN. Bd. 13. H. 4. 2023
Topp, Max; Dlugosz-Danecka, Monika; Skotnicki, Aleksander B. et al.
Safety of AFM11 in the treatment of patients with B-cell malignancies: findings from two phase 1 studiesTRIALS. Bd. 24. H. 1. 2023
Althoff, Friederike C.; Schaefer, Lisa V.; Acker, Fabian et al.
Survival benefit with checkpoint inhibitors versus chemotherapy is modified by brain metastases in patients with recurrent small cell lung cancerFRONTIERS IN ONCOLOGY. Bd. 13. 2023
Heidegger, Simon; Stritzke, Florian; Dahl, Sarah et al.
Targeting nucleic acid sensors in tumor cells to reprogram biogenesis and RNA cargo of extracellular vesicles for T cell-mediated cancer immunotherapyCELL REPORTS MEDICINE. Bd. 4. H. 9. 2023
Kropp, Korbinian N.; Fatho, Martina; Huduti, Enes et al.
Targeting the melanoma-associated antigen CSPG4 with HLA-C*07:01-restricted T-cell receptorsFRONTIERS IN IMMUNOLOGY. Bd. 14. 2023
Rejeski, Kai; Wang, Yucai; Albanyan, Omar et al.
The CAR-HEMATOTOX score identifies patients at high risk for hematological toxicity, infectious complications, and poor treatment outcomes following brexucabtagene autoleucel for relapsed or refractory MCLAMERICAN JOURNAL OF HEMATOLOGY. 2023
Illert, A. L.; Stenzinger, A.; Bitzer, M. et al.
The German Network for Personalized Medicine to enhance patient care and translational researchNATURE MEDICINE. Bd. 29. H. 6. 2023 S. 1298-1301